Marubi(SH:603983) Sou Hu Cai Jing·2025-12-15 11:56Core Viewpoint - The Chinese beauty brand Marubi Biotechnology (丸美生物) is preparing for a Hong Kong IPO after experiencing a modest stock performance in A-shares, with a year-to-date increase of only 5.3% compared to significant gains by its Hong Kong counterparts [2][3]. Group 1: Company Overview - Marubi Biotechnology was founded in April 2002 and went public on the Shanghai Stock Exchange in July 2019 [3]. - The company focuses on synthetic biology technology and has developed skincare products with anti-wrinkle, firming, and repairing effects, particularly through its core technology of recombinant collagen [3]. - Marubi operates two main brands: Marubi, which specializes in eye and facial care solutions, and Lianhuo, a cost-effective makeup brand focusing on base makeup products [3]. Group 2: Financial Performance - Marubi's revenue from 2022 to 2024 was reported as 1.732 billion RMB, 2.226 billion RMB, and 2.970 billion RMB, with a compound annual growth rate (CAGR) of 31.0% [6]. - The net profit for the same period was 167 million RMB, 278 million RMB, and 342 million RMB, achieving a CAGR of 43.0% [6]. - However, net profit growth has slowed significantly, with a year-on-year increase of only 2.9% in the first nine months of the current year [6]. Group 3: Sales Channels - Marubi's sales channels include both online and offline, with online direct sales through platforms like Douyin, Tmall, and JD.com, and offline sales through distributors to specialty stores, department store counters, and beauty salons [5]. - The proportion of revenue from online direct sales has increased from 46.4% in 2022 to 74.8% in the first nine months of 2025, indicating a strong shift towards online sales [7]. Group 4: Dividend Policy and Controversy - Marubi has faced controversy over its substantial dividend payouts, which totaled 76.2 million RMB, 100 million RMB, 309 million RMB, and 301 million RMB from 2022 to 2025 [12]. - The company's significant dividends have raised questions among investors, especially in light of declining net profit growth and the potential impact on cash reserves [11][12]. - The major shareholders, Sun Huaqing and Wang Xiaopu, hold approximately 80.8% of the company, leading to concerns about the alignment of interests between the company and its investors [12]. Group 5: Future Plans - Marubi plans to use the funds raised from its IPO for enhancing its online and offline consumer engagement capabilities, marketing activities, and expanding its R&D team [13]. - The company aims to improve its supply chain capabilities and general working capital through the proceeds from the IPO [13].